Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 82

1.

Conserved hippocampal cellular pathophysiology but distinct behavioural deficits in a new rat model of FXS.

Till SM, Asiminas A, Jackson AD, Katsanevaki D, Barnes SA, Osterweil EK, Bear MF, Chattarji S, Wood ER, Wyllie DJ, Kind PC.

Hum Mol Genet. 2015 Aug 4. pii: ddv299. [Epub ahead of print]

2.

Visual recognition memory: a view from V1.

Cooke SF, Bear MF.

Curr Opin Neurobiol. 2015 Jul 4;35:57-65. doi: 10.1016/j.conb.2015.06.008. [Epub ahead of print] Review.

PMID:
26151761
3.

Erratum: Visual recognition memory, manifested as long-term habituation, requires synaptic plasticity in V1.

Cooke SF, Komorowski RW, Kaplan ES, Gavornik JP, Bear MF.

Nat Neurosci. 2015 Jun;18(6):926. doi: 10.1038/nn0615-926d. No abstract available.

PMID:
26007217
4.

Visual recognition memory, manifested as long-term habituation, requires synaptic plasticity in V1.

Cooke SF, Komorowski RW, Kaplan ES, Gavornik JP, Bear MF.

Nat Neurosci. 2015 Feb;18(2):262-71. doi: 10.1038/nn.3920. Epub 2015 Jan 19. Erratum in: Nat Neurosci. 2015 Jun;18(6):926.

5.

Contribution of mGluR5 to pathophysiology in a mouse model of human chromosome 16p11.2 microdeletion.

Tian D, Stoppel LJ, Heynen AJ, Lindemann L, Jaeschke G, Mills AA, Bear MF.

Nat Neurosci. 2015 Feb;18(2):182-4. doi: 10.1038/nn.3911. Epub 2015 Jan 12.

6.

Microchip amplifier for in vitro, in vivo, and automated whole cell patch-clamp recording.

Harrison RR, Kolb I, Kodandaramaiah SB, Chubykin AA, Yang A, Bear MF, Boyden ES, Forest CR.

J Neurophysiol. 2015 Feb 15;113(4):1275-82. doi: 10.1152/jn.00629.2014. Epub 2014 Nov 26.

PMID:
25429119
7.

Higher brain functions served by the lowly rodent primary visual cortex.

Gavornik JP, Bear MF.

Learn Mem. 2014 Sep 15;21(10):527-33. doi: 10.1101/lm.034355.114. Print 2014 Oct. Review.

PMID:
25225298
8.

Learned spatiotemporal sequence recognition and prediction in primary visual cortex.

Gavornik JP, Bear MF.

Nat Neurosci. 2014 May;17(5):732-7. doi: 10.1038/nn.3683. Epub 2014 Mar 23.

9.

Divergent dysregulation of gene expression in murine models of fragile X syndrome and tuberous sclerosis.

Kong SW, Sahin M, Collins CD, Wertz MH, Campbell MG, Leech JD, Krueger D, Bear MF, Kunkel LM, Kohane IS.

Mol Autism. 2014 Feb 24;5(1):16. doi: 10.1186/2040-2392-5-16.

10.

How the mechanisms of long-term synaptic potentiation and depression serve experience-dependent plasticity in primary visual cortex.

Cooke SF, Bear MF.

Philos Trans R Soc Lond B Biol Sci. 2013 Dec 2;369(1633):20130284. doi: 10.1098/rstb.2013.0284. Print 2014 Jan 5. Review. Erratum in: Philos Trans R Soc Lond B Biol Sci. 2014 Apr 5;369(1639):20140021.

11.

STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study.

Erickson CA, Veenstra-Vanderweele JM, Melmed RD, McCracken JT, Ginsberg LD, Sikich L, Scahill L, Cherubini M, Zarevics P, Walton-Bowen K, Carpenter RL, Bear MF, Wang PP, King BH.

J Autism Dev Disord. 2014 Apr;44(4):958-64. doi: 10.1007/s10803-013-1963-z.

PMID:
24272415
12.

Is metabotropic glutamate receptor 5 upregulated in prefrontal cortex in fragile X syndrome?

Lohith TG, Osterweil EK, Fujita M, Jenko KJ, Bear MF, Innis RB.

Mol Autism. 2013 May 24;4(1):15. doi: 10.1186/2040-2392-4-15.

13.

Fragile X mental retardation protein and synaptic plasticity.

Sidorov MS, Auerbach BD, Bear MF.

Mol Brain. 2013 Apr 8;6:15. doi: 10.1186/1756-6606-6-15. Review.

14.

A cholinergic mechanism for reward timing within primary visual cortex.

Chubykin AA, Roach EB, Bear MF, Shuler MG.

Neuron. 2013 Feb 20;77(4):723-35. doi: 10.1016/j.neuron.2012.12.039.

15.

Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome.

Osterweil EK, Chuang SC, Chubykin AA, Sidorov M, Bianchi R, Wong RK, Bear MF.

Neuron. 2013 Jan 23;77(2):243-50. doi: 10.1016/j.neuron.2012.01.034.

16.

Lifting the mood on treating fragile X.

Osterweil EK, Kind PC, Bear MF.

Biol Psychiatry. 2012 Dec 1;72(11):895-7. doi: 10.1016/j.biopsych.2012.09.017. No abstract available.

PMID:
23121869
17.

The BCM theory of synapse modification at 30: interaction of theory with experiment.

Cooper LN, Bear MF.

Nat Rev Neurosci. 2012 Nov;13(11):798-810. doi: 10.1038/nrn3353. Review.

PMID:
23080416
18.

Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen.

Henderson C, Wijetunge L, Kinoshita MN, Shumway M, Hammond RS, Postma FR, Brynczka C, Rush R, Thomas A, Paylor R, Warren ST, Vanderklish PW, Kind PC, Carpenter RL, Bear MF, Healy AM.

Sci Transl Med. 2012 Sep 19;4(152):152ra128.

19.

Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial.

Berry-Kravis EM, Hessl D, Rathmell B, Zarevics P, Cherubini M, Walton-Bowen K, Mu Y, Nguyen DV, Gonzalez-Heydrich J, Wang PP, Carpenter RL, Bear MF, Hagerman RJ.

Sci Transl Med. 2012 Sep 19;4(152):152ra127.

20.

Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice.

Michalon A, Sidorov M, Ballard TM, Ozmen L, Spooren W, Wettstein JG, Jaeschke G, Bear MF, Lindemann L.

Neuron. 2012 Apr 12;74(1):49-56. doi: 10.1016/j.neuron.2012.03.009.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk